Antibody-drug conjugates (ADCs) are an innovative promising class of cancer therapeutics. ADCs are comprised three key components of an antibody (monoclonal antibody or bispecific antibody), a cytotoxic payload or other novel types of payload, and a linker. ADCs integrate chemotherapy and immunotherapy by combining the potency of payloads with the specificity of antibodies.
ICE Bioscience has established a biological and DMPK integrated platform for ADC screening and evaluation. The platform is dedicated to support a comprehensive service portfolio with various aspects of ADC development projects.
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
Get a quote
Go top
